Summit Therapeutics (SMMT) Cash from Financing Activities (2019 - 2026)

Summit Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 50.54% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $613.7 million (up 57.99% YoY), and the FY2025 full-year result was $617.5 million, up 61.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.8 million, down from $573.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $573.8 million in Q4 2025, with the low at -$23.6 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged $106.8 million across 5 years, with a median of $16.4 million in 2022.
• The largest YoY upside for Cash from Financing Activities was 250365.0% in 2024 against a maximum downside of 477.67% in 2024.
• Summit Therapeutics' Cash from Financing Activities stood at $520.1 million in 2022, then tumbled by 98.8% to $6.3 million in 2023, then tumbled by 477.67% to -$23.6 million in 2024, then surged by 2530.21% to $573.8 million in 2025, then plunged by 99.34% to $3.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.8 million (Q1 2026), $573.8 million (Q4 2025), and $33.8 million (Q3 2025), per Business Quant data.